Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/181758
Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC Study)
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Background: Ibrutinib demonstrated remarkable efficacy and favorable tolerability in patients with untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including those with high-risk genetic alterations. The IBRORS-CLL study assessed the characteristics, clinical management and outcome of CLL patients receiving ibrutinib in routine clinical practice in Spain. Patients: Observational, retrospective, multicenter study in CLL patients who started single-agent ibrutinib as first-line treatment or at first or second relapse between January 2016 and January 2019. Results: A total of 269 patients were included (median age: 70.9 years; cardiovascular comorbidity: 55.4%, including hypertension [47.6%] and atrial fibrillation [AF] [7.1%]). Overall, 96.7% and 69% of patients underwent molecular testing for del(17p)/TP53 mutation and IGHV mutation status. High-risk genetic features included unmutated IGHV (79%) and del(17p)/TP53 mutation (first-line: 66.3%; second-line: 23.1%). Overall, 84 (31.2%) patients received ibrutinib as first-line treatment, and it was used as second- and third-line therapy in 121 (45.0%) and 64 (23.8%) patients. The median progression-free survival and overall survival were not reached irrespective of del(17p)/TP53, or unmutated IGHV. Common grade ≥3 adverse events were infections (12.2%) and bleeding (3%). Grade ≥3 AF occurred in 1.5% of patients. Conclusion: This real-world study shows that single-agent ibrutinib is an effective therapy for CLL, regardless of age and high-risk molecular features, consistent with clinical trials. Additionally, single-agent ibrutinib was well tolerated, with a low rate of cardiovascular events. This study also emphasized a high molecular testing rate of del(17p)/TP53 mutation and IGHV mutation status in clinical practice according to guideline recommendations.
Matèries (anglès)
Citació
Citació
ABRISQUETA COSTA, Pau, LOSCERTALES, Javier, TEROL, Maria josé, RAMÍREZ PAYER, Ángel, ORTIZ, Macarena, PÉREZ FERNÁNDEZ, Inmaculada, CUELLAR GARCÍA, Carolina, FERNÁNDEZ DE LA MATA, Margarita, RODRÍGUEZ FERNÁNDEZ, Alicia, LARIO, Ana, DELGADO, Julio, GODOY, Ana, ARGUIÑANO PÉREZ, José mª, BERRUEZO, Mª josé, OLIVEIRA RAMOS, Ana carla, HERNÁNDEZ RIVAS, José ángel, GARCÍA MALO, Maria dolores, MEDINA, Ángeles, GARCÍA MARTIN, Paloma, OSORIO, Santiago, BALTASAR, Patricia, FERNÁNDEZ ZARZOSO, Miguel, MARCO, Fernando, VIDAL MANCEÑIDO, Mª jesús, SMUCLER SIMONOVICH, Alicia susana, LÓPEZ RUBIO, Montserrat, JARQUE, Isidro, SUAREZ CABRERA, Alexia, FERNÁNDEZ ÁLVAREZ, Rubén, LANCHARRO ANCHEL, Aima, RÍOS, Eduardo, LOSADA CASTILLO, María del carmen, PÉREZ PERSONA, Ernesto, GARCÍA MUÑOZ, Ricardo, RAMOS, Rafael, YÁÑEZ, Lucrecia, BELLO, José luis, LORIENTE, Cristina, ACHA, Daniel, VILLANUEVA, Miguel. Real-world characteristics and outcome of patients treated with single-agent ibrutinib for chronic lymphocytic leukemia in Spain (IBRORS-LLC Study). _Clinical Lymphoma Myeloma and Leukemia_. 2021. Vol. 21, núm. 12, pàgs. e985-e999. [consulta: 25 de desembre de 2025]. ISSN: 2152-2669. [Disponible a: https://hdl.handle.net/2445/181758]